Veliparib + Temozolomide in Metastatic Breast Cancer With and Without BRCA1/2 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
Breast Cancer Res Treat 2021 Oct 01;189(3)641-651, J Xu, TE Keenan, B Overmoyer, NM Tung, RS Gelman, K Habin, JE Garber, LW Ellisen, EP Winer, PE Goss, BY Yeap, BA Chabner, SJ IsakoffFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.